Suppression of Invasive Properties of Colorectal Carcinoma SW480 Cells by 15-Hydroxyprostaglandin Dehydrogenase Gene

REFERENCES

• McCormick D., Kibbe P. J., Morgan S. W. Colon cancer: prevention, diagnosis, treatment. Gastroenterol Nurs 2002; 25: 204–212
   PubMedGoogle Scholar
• Liang L., Qu L., Ding Y. Protein and mRNA characterization in human colorectal carcinoma cell lines with different metastatic potentials. Cancer Invest 2007; 25: 427–434
   PubMed Web of Science ®Google Scholar
• Charames G. S., Bapat B. Cyclooxygenase-2 knockdown by RNA interference in colon cancer. Int J Oncol 2006; 28: 543–549
   PubMed Web of Science ®Google Scholar
• Wang D., Wang H., Brown J., Daikoku T., Ning W., Shi Q., Richmond A., Strieter R., Dey S. K., DuBois R. N. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006; 203(4)941–951
   PubMed Web of Science ®Google Scholar
• Castellone M. D., Teramoto H., Williams B. O., Druey K. M., Gutkind J. S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005; 310(5753)1504–1510
   PubMed Web of Science ®Google Scholar
• Liu E. S., Ye Y. N., Shin V. Y., Wu W. K., Wong B. C., Cho C. H. Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice. Cancer Invest 2007; 25(8)750–757
   PubMed Web of Science ®Google Scholar
• Patsos H. A., Hicks D. J., Dobson R. R., Greenhough A., Woodman N., Lane J. D., Williams A. C., Paraskeva C. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 2005; 54(12)741–1750
   Google Scholar
• Ensor C M, Tai H H. NAD + -dependent 15-hydroxyprostaglandin dehydrogenase: A key enzyme for the catabolism of the prostaglandins. J Lipid Mediators 1995; 12: 313–319
   Google Scholar
• Anggard E., Larsson S. C., Samuelsson B. The distribution of 15-hydroxyprostaglandin dehydrogenase and prostaglandin D13-reductase in tissues of the swine. Acta Physiol Scand 1971; 81: 396–404
   PubMedGoogle Scholar
• Backlund M. G., Mann J. R., Holla V. R., Buchanan F. G., Tai H. H., Musiek E. S., Milne G. L., Katkuri S., DuBois R. N. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005; 280(5)3217–3723
   PubMed Web of Science ®Google Scholar
• Myung S. J., Rerko R. M., Yan M., Platzer P., Guda K., Dotson A., Lawrence E., Dannenberg A. J., Lovgren A. K., Luo G., Pretlow T. P., Newman R. A., Willis J., Dawson D., Markowitz S. D. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006; 103(32)12098–12102
   PubMed Web of Science ®Google Scholar
• Wolf I., O'Kelly J., Rubinek T., Tong M., Nguyen A., Lin B. T., Tai H. H., Karlan B. Y., Koeffler H. P. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006; 66(15)7818–7823
   PubMed Web of Science ®Google Scholar
• Yan M., Rerko R. M., Platzer P., Dawson D., Willis J., Tong M., Lawrence E., Lutterbaugh J., Lu S., Willson J. K., Luo G., Hensold J., Tai H. H., Wilson K., Markowitz S. D. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U SA 2004; 101(50)17468–17473
   PubMed Web of Science ®Google Scholar
• Myung S. J., Rerko R. M., Yan M., Platzer P., Guda K., Dotson A., Lawrence E., Dannenberg A. J., Lovgren A. K., Luo G., Pretlow T. P., Newman R. A., Willis J., Dawson D., Markowitz S. D. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006; 103(32)12098–12102
   PubMed Web of Science ®Google Scholar
• Sheng H., Shao J., Washington M. K., DuBois R. N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276: 18075–18081
   PubMed Web of Science ®Google Scholar
• Tsujii M., Kawano S., DuBois R. Cyclooxygenase-2 expression in human colon cancer cells increase metastatic potential. Proc Natl Acad Sci U SA 1997; 94: 3336–3340
   PubMed Web of Science ®Google Scholar
• Tsujii M., DuBois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501
   PubMed Web of Science ®Google Scholar
• Baumgartner G., Gomar-Hoss C., Sakr L., Ulsperger E., Wogritsch C. The impact of extracellular matrix on the chemical resistance of solid tumors—experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 1998; 131: 85–100
   PubMed Web of Science ®Google Scholar
• Dohadwala M., Luo J., Zhu L., Lin Y., Dougherty G. J., Sharma S., Huang M., Pold M., Batra R. K., Dubinett S. M. Non-small cell lung cancer cyclooxygenase-2 dependent invasion is mediated by CD44. J Biol Chem 2001; 276: 20809–20812
   PubMed Web of Science ®Google Scholar
• Ensor C. M., Yang J. Y., Okita R. T., Tai H. H. Cloning and sequence analysis of the cDNA for human placental NAD+-dependent 15-hydroxyprostaglandin dehydrogenase. J Biol Chem 1990; 265: 14888–14891
   PubMed Web of Science ®Google Scholar
• Ensor C. M., Tai H. H. Bacterial expression and site-directed mutagenesis of two critical residues (tyrosine-151 and lysine-155) of human placental NAD+ -dependent 15-hydroxyprostaglandin dehydrogenase. Biochim Biophys Acta 1994; 1208: 151–156
   PubMed Web of Science ®Google Scholar
• Tai H. H. Enzymatic synthesis of (15S)-[15-3H] prostaglandins and their use in the development of a simple and sensitive assay for 15-hydroxyprostaglandin dehydrogenase. Biochemistry 1976; 15: 4586–4592
   PubMed Web of Science ®Google Scholar
• Webb D. J., Parsons J. T., Horwitz A. F. Adhesion assembly, disassembly and turnover in migrating cells: over and over and over again. Nat Cell Biol 2002; 4: E97–E100
   PubMed Web of Science ®Google Scholar
• Huang G., Hu Z., Li M., Cui Y., Li Y., Guo L., Jiang W., Lu S. H. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. Carcinogenesis 2007; 28(11)2274–2281
   PubMed Web of Science ®Google Scholar
• Attiga F. A., Fernandez P. M., Weeraratna A. T., Manyak M. J., Patierno S. R. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000; 60: 4629–4637
   PubMed Web of Science ®Google Scholar
• Puolakkainen P. A., Brekken R. A., Muneer S., Sage E. H. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2004; 2: 215–224
   PubMed Web of Science ®Google Scholar
• Yamamoto S., Yan F., Zhou H., Tai H. H. Serine 331 is the major site of receptor phosphorylation induced by agents that activate protein kinase G in HEK 293 cells overexpressing thromboxane receptor. Arch Biochem Biophys 2001; 393: 97–105
   PubMed Web of Science ®Google Scholar
• Tong M., Tai H. H. Induction of NAD+ -linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem Biophys Res Commun 2000; 276: 77–81
   PubMed Web of Science ®Google Scholar
• Celis J. E., Ostergaard M., Basse B. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progress of human bladder transitional carcinoma. Cancer Res 1996; 56: 4782–4790
   PubMed Web of Science ®Google Scholar
• Gee J. R., Chen I. L., Montoya R. G., Sabichi A. L., Grossman B., Liebert M. Down regulation of prostaglandin dehydrogenase in invasive transitional cell carcinoma. Proc Am Assoc Cancer Res 2001; 42: 264–269
   Google Scholar
• Ding Y., Tong M., Liu S., Moscow J. A., Tai H. H. NAD+ -linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005; 26(1)65–72
   PubMed Web of Science ®Google Scholar
• Liu Z., Wang X., Lu Y., Han S., Zhang F., Zhai H., Lei T., Liang J., Wang J., Wu K., Fan D. Expression of 15-PGDH is down-regulated by COX-2 in gastric cancer. Carcinogenesis 2008, Jan 3; [Epub ahead of print]
   Google Scholar
• Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761–3764
   PubMed Web of Science ®Google Scholar
• Larkins T. L., Nowell M., Singh S., Sanford G. L. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006; 181: 1471–1186
   Google Scholar
• Hazra S., Batra R. K., Tai H. H., Sharma S., Cui X., Dubinett S. M. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007; 71(6)1715–1720
   PubMed Web of Science ®Google Scholar
• Tong M., Ding Y., Tai H. H. Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis 2006; 27(11)2170–2179
   PubMed Web of Science ®Google Scholar
• Takahashi Y., Kawahara F., Noguchi M., Miwa K., Sato H., Seiki M., Inoue H., Tanabe T., Yoshimoto T. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett 1999; 460: 145–148
   PubMed Web of Science ®Google Scholar
• Sivula A., Talvensaari-Mattila A., Lundin J., Joensuu H., Haglund C., Ristimaki A., Turpeenniemi-Hujanen T. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005; 89: 215–220
   PubMed Web of Science ®Google Scholar
• Brooks P. C., Stromblad S., Sanders L. C. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683–693
   PubMed Web of Science ®Google Scholar
• Dohadwala M., Batra R. K., Luo J., Lin Y., Krysan K., Pold M., Sharma S., Dubinett S. M. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002; 277: 30828–30833
   Google Scholar
• Han C., Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005; 280: 24053–24063
   PubMed Web of Science ®Google Scholar
• Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999; 13: 35–48
   PubMed Web of Science ®Google Scholar
• Fernández J. C., Vizoso F. J., Corte M. D., Gava R. R., Corte M. G., Suárez J. P., García-Muñíz J. L., García-Morán M. CD44s expression in resectable colorectal carcinomas and surrounding mucosa. Cancer Invest 2004; 22(6)878–885
   PubMed Web of Science ®Google Scholar
• Dohadwala M., Batra R. K., Luo J., Lin Y., Krysan K., Pold M., Sharma S., Dubinett S. M. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2 dependent invasion. J Biol Chem 2002; 277(52)50828–50833
   PubMed Web of Science ®Google Scholar
• Lopez J. I., Camenisch T. D., Stevens M. V., Sands B. J., McDonald J., Schroeder J. A. CD44 Attenuates Metastatic Invasion during Breast Cancer Progression. Cancer Research 2005; 65: 6755–6763
   PubMed Web of Science ®Google Scholar